Chimeric Antigen Receptor T Cell Stocks List

Chimeric Antigen Receptor T Cell ETFs
Recent Chimeric Antigen Receptor T Cell News

Symbol	Grade	Name	% Change
GDTC	C	CytoMed Therapeutics Limited	-0.46
JANX	C	Janux Therapeutics, Inc.	-5.02
PSTX	D	Poseida Therapeutics, Inc.	-0.37
CRBU	D	Caribou Biosciences, Inc.	1.02
TSVT	F	2seventy bio, Inc.	1.61
NTLA	F	Intellia Therapeutics, Inc.	5.18
SNTI	F	Senti Biosciences, Inc.	0.00
CARM	F	Carisma Therapeutics, Inc.	-1.69
ACET	F	Adicet Bio, Inc.	-5.49
NKTX	F	Nkarta, Inc.	-2.40

View As Page of Charts

Related Industries: Biotechnology

Related ETFs - A few ETFs which own one or more of the above listed Chimeric Antigen Receptor T Cell stocks.

Symbol	Grade	Name	Weight
CNCR	F	Loncar Cancer Immunotherapy ETF	4.96
GNOM	F	Global X Genomics & Biotechnology ETF	4.5
ARKG	F	ARK Genomic Revolution Multi-Sector ETF	3.89
CANC	D	Tema Oncology ETF	3.01
ARKK	C	ARK Innovation ETF	2.09

View all Chimeric Antigen Receptor T Cell ETFs...

Compare ETFs

Compare ARKG to ARKK Compare CANC to ARKK Compare GNOM to CANC

Chimeric Antigen Receptor T Cell Stocks Recent News

Date	Stock	Title
Nov 20	CRBU	Caribou Biosciences to Participate in Upcoming Investor Conferences
Nov 20	GDTC	Update on Clinical Milestone - CytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies
Nov 19	NTLA	Intellia Therapeutics Announces Promising CRISPR Therapy Results
Nov 19	NTLA	ReCode to secure funds for cystic fibrosis gene correction treatments
Nov 19	NTLA	Intellia Therapeutics price target lowered to $70 from $80 at Wells Fargo
Nov 19	JANX	Janux Therapeutics: Believable Theory, Strong Early Data, Needs Confirmation
Nov 19	NTLA	Intellia Therapeutics' Gene Therapies Fall Short Of Breakthroughs (Rating Downgrade)
Nov 18	ACET	Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma
Nov 18	NTLA	Intellia’s gene editing therapy shows early potential in rare heart condition
Nov 18	ACET	Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases
Nov 18	NTLA	CRISPR therapy from Intellia may ameliorate rare heart disorder, data suggest
Nov 18	ACET	Is Adicet Bio (NASDAQ:ACET) In A Good Position To Deliver On Growth Plans?
Nov 17	CARM	Carisma Therapeutics Presents Promising New Preclinical Data on Engineered Macrophages for the Treatment of Liver Fibrosis at AASLD The Liver Meeting® 2024
Nov 16	NTLA	Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis
Nov 16	ACET	Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024
Nov 16	JANX	Bitdeer Technologies, PBF Energy, and More Stocks See Action From Activist Investors
Nov 15	TSVT	US$8.25: That's What Analysts Think 2seventy bio, Inc. (NASDAQ:TSVT) Is Worth After Its Latest Results
Nov 15	SNTI	Senti Biosciences GAAP EPS of -$6.31

Chimeric Antigen Receptor T Cell: Chimeric Antigen Receptor T Cell (CAR-T) is a type of immunotherapy that uses a patient’s own T cells to fight cancer. The T cells are genetically modified to express a special receptor, called a chimeric antigen receptor (CAR), which is designed to recognize and bind to a specific protein found on the surface of cancer cells. Once the CAR-T cells bind to the cancer cells, they can kill them. CAR-T therapy has been used to treat certain types of blood cancers, such as leukemia and lymphoma, and is being studied for other types of cancer.

Browse All Tags